(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Showing 1 - 6 of 6 records.
This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. ...More
The investigators are testing intravenous topotecan and vincristine in combination with subtenon carboplatin in the hopes of finding a drug combination that may be effective against retinoblastoma that has come back or is resistant to other treatment. ...More
This study will test if giving Topotecan directly into the blood vessel of the eye will improve the treatment of retinoblastoma. This method is referred to as "selective intraophthalmic artery chemotherapy" (SIOAC). ...More
This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth....More
This phase I trial studies the side effects and the best dose of crizotinib giving together with combination chemotherapy in treating younger patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. Crizotinib may stop the growth of tumor or cancer cells by blocking some...More
This phase I/II trial studies the side effects
and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in
treating younger patients with solid tumors that have come back or that have
not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan
hydrochloride may stop the...More
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center